Parikh, Apurvasena
AbbVie (United States)
2 papers on CoChatORCID 0000-0003-3711-8718
Most cited papers
- Verified
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.
Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C. W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., & Xu, S. (2025) · Clinical Pharmacology & Therapeutics
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 7
- Verified
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free